Previous studies revealed that PBX1 ranked the third in the differentially expressed genes about development and progression of breast cancer (BC). Nevertheless, the role of PBX1 contributing to progression of BC has been unevaluated. Here, on the basis of ONCOMINE and GOBO databases, we compared BC samples with normal controls about the expression of PBX1 in various types of cancers, as well as their related expression levels in cancer cell lines by Cancer Cell Line Encyclopedia (CCLE) analysis. It was also found that, when compared with normal controls, PBX1 was markedly higher expressed not only in BC samples but also in BC cell lines, and coexpressed with EMP2 by ONCOMINE and CCLE coexpression analysis, which was also expressed higher in BC samples and BC cell lines similarly. According to Kaplan–Meier plotter, we further explored the prognostic functions of PBX1 and EMP2 in different molecular subtypes of BC, respectively. We demonstrated that overexpression of PBX1 mRNA was correlated with worse survival in luminal B subtype BC, whereas increased EMP2 expression was associated with shorter relapse-free survival in estrogen receptor (ER)-negative patients. Combining with previous studies, we could make a conclusion that coexpression of PBX1 and EMP2 predicts poor prognosis in ER-negative BC, which could be effective biomarkers for BC.

中文翻译：

---

通过数据挖掘将 PBX1 和 EMP2 共表达作为雌激素受体阴性乳腺癌的预后生物标志物


此前的研究表明，PBX1在乳腺癌（BC）发生和进展的差异表达基因中排名第三。然而，PBX1 在 BC 进展中的作用尚未得到评估。在此，我们基于ONCOMINE和GOBO数据库，通过癌症细胞系百科全书（CCLE）分析比较了BC样本与正常对照中PBX1在各类癌症中的表达，以及其在癌细胞系中的相关表达水平。通过ONCOMINE和CCLE共表达分析还发现，与正常对照相比，PBX1不仅在BC样本中表达明显较高，而且在BC细胞系中也表达较高，并且通过ONCOMINE和CCLE共表达分析与EMP2共表达，PBX1在BC样本和BC中也表达较高。细胞系类似。根据Kaplan-Meier绘图仪，我们进一步探讨了PBX1和EMP2分别在BC不同分子亚型中的预后功能。我们证明，PBX1 mRNA 的过度表达与管腔 B 亚型 BC 的较差生存期相关，而 EMP2 表达增加与雌激素受体 (ER) 阴性患者的无复发生存期较短相关。结合以往的研究，我们可以得出这样的结论：PBX1和EMP2的共表达预示着ER阴性BC的不良预后，这可能是BC的有效生物标志物。